ASND
- Ascendis Pharma A/S
()
Overview
Company Summary
Ascendis Pharma A/S (ASND) is a biopharmaceutical company that specializes in developing innovative therapies to address unmet medical needs. The company focuses on creating drug candidates based on its proprietary TransCon technology platform.
TransCon technology allows Ascendis Pharma to improve the properties and therapeutic benefits of existing drugs by extending their duration of action, enhancing their efficacy, and reducing their side effects. This platform involves linking a drug molecule to an inert carrier, creating a prodrug that can be administered to patients using standard injection or infusion methods.
Ascendis Pharma's research and development efforts are concentrated on developing therapies for rare endocrine diseases, which are characterized by hormone imbalances, as well as other indications. The company's lead product candidate, TransCon hGH, is being developed as a once-weekly growth hormone therapy for children with growth hormone deficiency.
By utilizing TransCon technology, Ascendis Pharma aims to provide patients with convenient treatments that reduce the frequency of administration and improve adherence to therapy. The company's goal is to make a positive impact on patients' lives by providing effective and long-lasting drug therapies for diseases that currently lack adequate treatment options.
In addition to developing its own drug candidates, Ascendis Pharma actively seeks collaborations and strategic partnerships with other pharmaceutical companies to leverage its proprietary technology platform. These collaborations provide both financial resources and expertise to advance the discovery and development of new treatments.
Overall, Ascendis Pharma is dedicated to transforming the lives of patients by developing innovative therapies that address the unmet medical needs in rare endocrine diseases and other therapeutic areas utilizing its proprietary TransCon technology.